Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer

Praveena Cheruvu, Su K Metcalfe, Justin Metcalfe, Yuhchyau Chen, Paul Okunieff, Michael T Milano, Praveena Cheruvu, Su K Metcalfe, Justin Metcalfe, Yuhchyau Chen, Paul Okunieff, Michael T Milano

Abstract

Background: Standard therapy for metastatic non small cell lung cancer (NSCLC) includes palliative systemic chemotherapy and/or radiotherapy. Recent studies of patients with limited metastases treated with curative-intent stereotactic body radiation therapy (SBRT) have shown encouraging survival. We hypothesized that patients treated with SBRT for limited metastases have comparable outcomes with those treated with curative-intent radiation for Stage III NSCLC.

Methods: We retrospectively reviewed the records of NSCLC patients treated with curative-intent radiotherapy at the University of Rochester from 2000-2008. We identified 3 groups of patients with NSCLC: stage III, stage IV, and recurrent stage IV (initial stage I-II). All stage IV NSCLC patients treated with SBRT had ≤ 8 lesions.

Results: Of 146 patients, 88% had KPS ≥ 80%, 30% had > 5% weight loss, and 95% were smokers. The 5-year OS from date of NSCLC diagnosis for stage III, initial stage IV and recurrent stage IV was 7%, 14%, and 27% respectively. The 5-year OS from date of metastatic diagnosis was significantly (p < 0.00001) superior among those with limited metastases (≤ 8 lesions) versus stage III patients who developed extensive metastases not amenable to SBRT (14% vs. 0%).

Conclusion: Stage IV NSCLC is a heterogeneous patient population, with a selected cohort apparently faring better than Stage III patients. Though patients with limited metastases are favorably selected by virtue of more indolent disease and/or less bulky disease burden, perhaps staging these patients differently is appropriate for prognostic and treatment characterization. Aggressive local therapy may be indicated in these patients, though prospective clinical studies are needed.

Figures

Figure 1
Figure 1
represents the overall survival from date of diagnosis for the various stage groupings. The blue line represents Stage III (whom did not progress to Stage IV, maroon line represents Stage III which progressed to Stage IV, green line represents the initial stage IV patients and lastly the gold line represents the Stage I/II patients that progressed to Stage IV.
Figure 2
Figure 2
represents the overall survival from date of failure. The blue line represents Stage III which progressed to Stage IV, green line represents the Stage I/II patients that progressed to Stage IV, and lastly the maroon line represents initial stage IV patients.

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
    1. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. 6. New York: Springer; 2002.
    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 2005;13:8–10.
    1. Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, Lu D. Local Surgical, Ablative and Radiation Treatment of Metastases. CA Cancer J Clin. 2009;59:145–170. doi: 10.3322/caac.20013.
    1. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, Okunieff P. A Prospective Pilot study of Curative Intent Stereotactic Body Radiotherapy in Patients with 5 or fewer Oligometastatic Lesions. Cancer. 2008;112:650–658. doi: 10.1002/cncr.23209.
    1. Milano MT, Katz AW, Schell MC, Philip A, Okunieff P. Descriptive Analysis of Oligometastatic Lesions Treated with Curative-Intent Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(5):1516–22. doi: 10.1016/j.ijrobp.2008.03.044.
    1. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA. Phase 1 Study of Concurrent Sunitinib and Image Guided Radiotherapy followed by Maintenance Sunitinib for Patients with Oligometastases: Acute Toxicity and Preliminary Response. Cancer. 2009;115(15):3571–80. doi: 10.1002/cncr.24412.
    1. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR. An Initial Report of Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease. Clin Cancer Res. 2008;14(160):5255–9.
    1. Milano MT, Constine LS, Okunieff P. Normal Tissue Toxicity after Small Field Hypofractionated Stereotactic Body Radiation. Radiat Oncol. 2008;3:36. doi: 10.1186/1748-717X-3-36.
    1. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Limited Hepatic Metastases. Int J Radiat Oncol Biol Phys. 2006;67:793–798.
    1. Okunieff P, Petersen AL, Philip A, Milano MR, Katz AW, Boros L, Schell MC. Stereotactic Body radiation Therapy (SBRT) for Lung Metastases. Acta Oncol. 2006;45:808–817. doi: 10.1080/02841860600908954.
    1. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in Long-Term Survival Following liver resection for Hepatic Colorectal Metastases. Ann surg. 2002;235:759–766. doi: 10.1097/00000658-200206000-00002.
    1. Sternberg DI, Sonett jr. Surgical Therapy of Lung Metastases. Semin Oncol. 2007;133:967–972.
    1. Tanvetyanon T, Robinson L, Schell MJ, Strong VE, Kapoor R, Coit DG, Bepler G. Outcomes of Adrenalectomy for Isolated versus Metachronous Adrenal Metastases in Non-Small- Cell Lung Cancer: A Systematic Review and Pooled Analysis. J Clin Oncol. 2008;26:1142–1147. doi: 10.1200/JCO.2007.14.2091.
    1. Pfannschmidt J, Dienemann H. Surgical Treatment of Oligometastatic Non-Small Cell Lung Cancer. Lung Cancer. 2010;69:251–258. doi: 10.1016/j.lungcan.2010.05.003.
    1. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27:1579–1584. doi: 10.1200/JCO.2008.19.6386.
    1. Kavanagh BD, McGarry RC, Timmerman RD. Extracranial Radiosurgery (Stereotactic Body Radiation Therapy) for Oligometastases. Semin Radiat Oncol. 2006;16(2):77–84. doi: 10.1016/j.semradonc.2005.12.003.
    1. Lo SS, Sahgal A, Wang JZ, Mayr NA, Sloan A, Mendel E, Chang EL. Stereotactic Body Radiation Therapy for Spinal Metastases. Discov Med. 2010;9(47):289–96.
    1. Rusthoven KE, Kavanaugh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases. J Clin Oncol. 2009;27(10):1572–8. doi: 10.1200/JCO.2008.19.6329.
    1. Chang EL, Shiu AS, Mendel E, Mathews LA, Mahajan A, Allen PK, Weinberg JS, Brown BW, Wang XS, Woo SY, Cleeland C, Maor MH, Rhines LD. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine. 2007;7:151–60. doi: 10.3171/SPI-07/08/151.
    1. Curran WJ, Scott CB, Langer CJ, Komaki R, Lee S, Hauser S, Movsas B, Wasserman T, Sause W, Cox JD. Proc Am Soc Clin Oncol(ASCO) abstr. #2499. Chicago; 2003. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410; p. 621.
    1. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN, Burris H, Gumerlock P, Kuebler JP, Bearden JD, Crowley J, Livingston R. Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non-Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504. JCO. 2003;21(10):2004–2010. doi: 10.1200/JCO.2003.04.197.
    1. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a Role for Consolidative Stereotactic Body Radiation Therapy Following First-Line Systemic Therapy for Metastatic Lung Cancer? A Patterns-of-Failure Analysis. Acta Oncologica. 2009;48:578–583. doi: 10.1080/02841860802662722.
    1. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, Vokes EE, Weichselbaum RR. Analysis of Further Disease Progression in Metastatic NSCLC: Implications for Locoregional Treatment. Int Journal of Oncology. 2004;25:1677–1683.
    1. Khan AJ, Mehta PS, Zusag TW, Bonomi PD, Penfield Faber L, Shott S, Abrams RA. Long term Disease Free Survival Resulting from Combined Modality Management of Patients Presenting with Oligometastatic NSCLC. Radiotherapy and Oncology. 2006;81:163–167. doi: 10.1016/j.radonc.2006.09.006.
    1. Chawla S, Chen Y, Katz AW, Muhs AG, Philip A, Okunieff P, Milano MT. Stereotactic Body Radiotherapy for Treatment of Adrenal Metastases. Int J Radiat Oncol Biol Phys. 2009;75(1):71–5. doi: 10.1016/j.ijrobp.2008.10.079.
    1. Lee P, Weerasuriya DK, Lavori PW, Hara W, Maxim PD, Le QT, Wakelee HA, Donington JS, Graves EE, Loo BW. Metabolic Tumor Burden Predicts for Disease Progression and Death in Lung Cancer. IJROBP. 2007;69(2):328–333.
    1. Bradley J, Ieumwananonthachai N, Purdy JA, Wasserman TH, Lockett MA, Gramham MV, Perez CA. Gross Tumor Volume Critical Prognostic Factor in Patients Treated with Three Dimensional Conformal Radiotherapy for NSCLC. IJROBP. 2002;52(1):49–57.
    1. Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S. Prognostic factors for survival in Stage III non-small-cell-lung cancer treated with definitive radiation therapy: impact of tumor volume. IJROBP. 2006;64:449–454.
    1. Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, Tsubota N. Effect of Tumor Size on Prognosis in Patients with Non Small Cell Lung Cancer: the Role of Segmentectomy as a Type of Lesser Resection. J Thoracic Cardiovasc Surg. 2005;129:87–93. doi: 10.1016/j.jtcvs.2004.04.030.
    1. Oh Y, Taylor S, Bekele BN, Debnam JM, Allen PK, Suki D, Sawaya R, Komaki R, Stewart DJ, Karp DD. Number of Metastatic Sites is a Strong Predictor of Survival in Patients with Nonsmall Cell Lung Cancer With or Without Brain Metastases. Cancer. 2009;115:2930–2938. doi: 10.1002/cncr.24333.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere